Not checkedNot checked for notices yet.
Uso de infliximabe em paciente com artrite reumatoide e hepatite B crônica Use of infliximab in a patient with rheumatoid arthritis and chronic hepatitis B
Eloisa Doubrawa, Renê Augusto de Mattos Ricca, Tiago Osternack Malucelli and 3 more
Revista Brasileira de Reumatologia · 2012
doi:10.1590/s0482-50042012000400015 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Os agentes anti-TNF-α emergiram como potente tratamento para os pacientes com artrite reumatoide que não respondem às drogas modificadoras de doença convencionais. Por induzir à imunossupressão, essas drogas têm como principal complicação o aumento da suscetibilidade a várias infecções. A reativação do vírus da hepatite B (HBV) é um dos efeitos colaterais mais preocupantes em pacientes recebendo agentes anti-TNF-α com infecção pelo HBV. Descrevemos o caso de um paciente de 56 anos com quadro de hepatite B estável, com boa resposta à associação dos antivirais lamivudina e tenofovir quando iniciou infliximabe. O paciente obteve boa resposta ao anti-TNF-α, atingindo remissão da doença. Durante os 30 meses de tratamento com o biológico, manteve função hepática estável, sem reativação do HBV.<br>Anti-TNF-α agents have emerged as a potent treatment for patients with rheumatoid arthritis unresponsive to conventional disease-modifying antirheumatic drugs. Increased susceptibility to infections induced by these drugs is the main complication of their use. Reactivation of hepatitis B virus (HBV) is one of the most worrisome side effects in patients with HBV infection receiving anti-TNF-α. We report the case of a 56-year-old male patient with stable hepatitis B and good response to the antiviral combination of lamivudine and tenofovir when infliximab was started. The patient went into remission. During the 30-month treatment with the biologic, his liver function remained stable, with no HBV reactivation.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.